About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

GEnomic Medicine in Kidney Transplantation Study | Clinical Trials | Clareo Health

Back to clinical trial search

Not Yet RecruitingNCT06365411

GEnomic Medicine in Kidney Transplantation Study

Investigator led, prospective, observational cohort study to detect genomic features which can predict outcomes following kidney transplantation. 1. Determine non-HLA genomic mismatches between donor...

Lead sponsor: Western Sydney Local Health District•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Contacts

Jennifer SY Li, MBBS, FRACP

CONTACT

612 88905555 jennifer.li@health.nsw.gov.au

Philip J O'Connell, MBBS, FRACP

CONTACT

612 88905555 philip.oconnell@sydney.edu.au

Sponsors

Lead Sponsor

Western Sydney Local Health District

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. able to provide informed consent (interpreter permitted) for enrolment
•2. consenting to longitudinal follow up (can withdraw post enrolment)
•3. consenting to provide samples for biobanking, including blood, urine, faecal and/or kidney biopsy tissue (collected prospectively, separate to routine care)

Exclusion Criteria

•1. unable (or unwilling) to provide consent, or
•2. have life-expectancy less than 6-months, or
•3. have received a haematopoietic stem cell transplant in the past 5 years.

Related studies

RECRUITINGPhase 2/3

A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

NCT07412470 · Kidney Transplant Rejection

Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease

NCT06910969 · Bone Marrow Transplant Complications, Graft-versus-Host Disease

RECRUITINGPhase 3

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

NCT03394365 · Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, and more

Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA

NCT07415876 · Kidney Transplant Rejection

Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab

NCT07006532 · Kidney Transplant Rejection

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 28, 2025Terms

Trial snapshot

StatusNOT_YET_RECRUITING

Phase—

Enrollment1,000

Start dateJun 2025

Last updatedMar 28, 2025

Condition

Transplant Complication Kidney Transplant Rejection

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 28, 2025Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions